Drug Approval | April 10, 2024
Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
The Pregabalin capsules has a market size of ~US$248 mn per IQVIA
Arco Lab now holds a 50% stake in Neviton
The product has been in-licensed from Strides and will be commercialized by Amneal
The Product will be manufactured at the company's facility in Bengaluru
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products
The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)